Antiplatelet agents for chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Palmer, Suetonia C ^a   Di Micco, Lucia ^b   Razavian, Mona ^c   Craig, Jonathan C ^d,e   Perkovic, Vlado ^c   Pellegrini, Fabio ^f,g   Jardine, Meg J ^h   Webster, Angela C ^d,e,i   Zoungas, Sophia ^j   Strippoli, Giovanni F M ^d,e,k,l,m  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f Consorzio Mario Negri Sud ^*  (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^h Department of Microbiology and Infectious Diseases   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j MONASH UNIVERSITY   (Australia)

^k UNIVERSITY OF BARI   (Italy)

^l MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^m Medical Scientific Office   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; THIENOPYRIDINE DERIVATIVE; ABCIXIMAB; ACETYLSALICYLIC ACID; CANGRELOR; CAPTOPRIL; CILOSTAZOL; DEFIBROTIDE; DIPYRIDAMOLE; ELINOGREL; EPTIFIBATIDE; HEPARIN; PICOTAMIDE; PRASUGREL; PREDNISONE; SIMVASTATIN; SULFINPYRAZONE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DRUG WITHDRAWAL; FATALITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; VASCULAR ACCESS; VASCULAR PATENCY; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTINUOUS INFUSION; DRUG MEGADOSE; END STAGE RENAL DISEASE; GASTROINTESTINAL HEMORRHAGE; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; PROTEINURIA; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84985034232     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008834.pub3     Document Type: Review

References (175)

1. Abdul-Rahman IS, Al-Howaish AK. Warfarin versus aspirin in preventing tunneled hemodialysis catheter thrombosis: a prospective randomized study. Hong Kong Journal of Nephrology 2007;9(1):23-30
2. Anderson M, Dewar P, Fleming LB, Hacking PM, Morley AR, Murray S, et al. A controlled trial of dipyridamole in human renal transplantation and an assessment of platelet function studies in rejection. Clinical Nephrology 1974;2 (3):93-9
3. Andrassy K,Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: Results of a prospective double blind study. Klinische Wochenschrift 1974;52(7): 348-9
4. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. Journal of the American College of Cardiology 2007;49(19):1982-8
5. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). American Journal of Cardiology 2009;103(10):1359-63
6. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, et al. An analysis of mortality rates with dualantiplatelet therapy in the primary prevention population of the CHARISMA trial. European Heart Journal 2007;28 (18):2200-7
7. Cheng IK, Fang GX, Wong MC, Ji YL, Chan KW, Yeung HW. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 1998;4(1-2):19-26
8. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of shortand long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008; 155(4):687-93
9. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19): 2411-20
10. Creek R. Ticlopidine. Patency of haemodialysis access sites. Guildford Sanofi Winthrop. Internal report 1990
11. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. European Journal of Cardiovascular Prevention & Rehabilitation 2007; 14(2):312-8
12. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. New England Journal of Medicine 2001; 345(7):494-502
13. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008;299(18): 2164-71
14. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clinical Trials 2005;2(5):413-22
15. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al. Dialysis access consortium (DAC) trial design: clopidogrel prevention of early AV fistula thrombosis [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):229A
16. Dixon B, Beck G, Meyers C, Kusek J, Feldman H, DAC Study Group. Effect of aspirin (ASA) on primary unassisted graft patency in the dialysis access consortium (DAC) graft trial [abstract]. Journal of the American Society of Nephrology 2008;19(Abstract Issue):256A
17. Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, et al. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clinical Trials 2005;2(5):400-12
18. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Dialysis Access Consortium (DAC) Trial design: sustained-release dipyridamole plus aspirin (D/A) to prevent graft failure [abstract]. Journal of the American Society of Nephrology 2002;10(Abstract Issue):232A
19. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. New England Journal ofMedicine 2009;360(21):2191-201
20. Dodd NJ, Turney JH, Weston MJ. Ticlopidine preserves vascular access for haemodialysis [abstract 326F]. Proceedings of the VI International Congress of Mediterranean League Against Thrombosis. 1980
21. Donadio JV Jr, Anderson CF, Mitchell JC 3rd, Holley KH, Ilstrup DM, Fuster V, et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of plateletinhibitor therapy. New England Journal of Medicine 1984; 310(22):1421-6
22. Ell S,Mihindukulasuriya JC, O'Brien JR, Polak A, Vernham G. Ticlopidine in the prevention of blockage of fistulae and shunts. Haemostasis 1982; Vol. 12:180
23. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. New England Journal of Medicine 1994;330(14):956-61
24. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343(8902):881-6
25. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278(6):479-84
26. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. New England Journal of Medicine 1997;336(24):1689-96
27. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation 1999;99(15):1951-8
28. EPISTENT Investigators. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122): 87-92
29. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354(9195):2019-24
30. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268 (10):1292-300
31. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effects of ticlopidine in arteriovenous fistulas for hemodialysis. Artificial Organs 1985;9(1):61-3
32. Frascà GM, Vangelista A, Raimondi C, Bonomini V. Prevention of vascular graft lesions in renal transplant recipients with a new antithrombotic agent (Defibrotide): a controlled study. Life Support System 1986;4(3):231-7
33. Bonomini V, Vangelista A, Stefoni S, ScolariMP, FrascàGM, Raimondi C. Use of defibrotide in renal transplantation in man. Haemostasis 1986;16 Suppl 1:48-50
34. Frascà GM, Cianciolo G. A clinical trial with defibrotide in IgA nephritis (IgA-GN) with impaired renal function [abstract]. Nephrology Dialysis Transplantation 1995;10(6): 968
35. Frascà GM, Martello M, Canova C, Isola E, Vangelista A, Bonomini V. Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis. Clinical Drug Investigation 1997;13 (4):185-91
36. Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Clinical Drug Investigation 1997;13(4):185-91
37. Frascà GM, Martello M, Sestigiani E, Canova C, Vangelista A, Bonomini V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrology Dialysis Transplantation 1996;11(2):392-3
38. Ghorbani A, Aalamshah M, Shahbazian H, Ehsanpour A, Aref A. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian Journal of Nephrology 2009;19(2):57-61
39. Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, et al. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 1998;47(3):423-30
40. Gonzalez MT, Castelao AM, Valles M, Cruzado JM, Mauri JM. Platelet antiaggregants (PA) could decrease the rate of progression of chronic renal failure (CRF) in diabetic patients (DP) treated previously with angiotensin converting enzyme inhibitors (ACEI) [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:200
41. Gröntoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scandinavian Journal of Urology & Nephrology 1985;19(1):55-7
42. Gröntoft K, Larsson R, Mulec H, Weiss LG, Dickinson JP. Ticlopidine in fistula surgery: double-blind comparison against placebo on the rate of early occlusion of arteriovenous fistulae [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem (Israel). 1993:398
43. Gröntoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scandinavian Journal of Urology & Nephrology 1998;32(4):276-83
44. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. New England Journal of Medicine 1979;301(11):577-9
45. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118):1755-62
46. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology 2010;56(12):956-65
47. Kolloch RE, Rahn KH. The Hypertension Optimal Treatment (HOT) study: Results of 12-month treatment related to age [Die 'Hyperyension Optimal Treatment' (HOT)-Studie: Behandlungsergebnisse nach Zwolfmonatiger Therapie in Abhangigkeit vom Alter]. Deutsche Medizinische Wochenschrift 1998;123(1-2):1-5
48. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology 2001;12(2):218-25
49. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349(9063):1422-8
50. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, et al. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Journal of the American College of Cardiology 1998;31(7): 1518-24
51. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. New England Journal of Medicine 1974;290 (6):304-6
52. Kauffmann HM, Adams MB, Hebert LA, Walczak PM. Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings 1980;12(2):311-4
53. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. Journal of the American Society of Nephrology 2003;14(9):2313-21
54. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Combination aspirin plus clopidogrel in the prevention of hemodialysis access graft thrombosis [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):291A
55. Khajehdehi P, Roozbeh J, Mostafavi H. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scandinavian Journal of Urology & Nephrology 2002;36(2):145-8
56. Kobayashi K,Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis: a multicenter collaborative double blind study. Thrombosis Research 1980;20(2):255-61
57. Kooistra MP, van Es A. Effects of low dose aspirin on thrombovascular accidents during treatment with rHuEpo: a multicentre, controlled, cross-over study [abstract]. Nephrology Dialysis Transplantation 1993;8:277
58. KooistraMP, van Es A,Marx JJ,HertsigML, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrology Dialysis Transplantation 1994;9(8):1115-20
59. Michie DD, Wombolt DG. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Current Therapeutic Research Clinical & Experimental 1977;22(1): 196-204
60. Middleton DA, Deichsel G. The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Berlin, Germany: Boehringer Ingelheim. Internal report 1992
61. Ogawa S, Mori T, Nako K, Ishizuka T, Ito S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(2):362-8
62. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122(11):1056-67
63. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105(20):2361-6
64. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. New England Journal of Medicine 1998;339(7): 436-43
65. Quarto Di Palo F, Elli A, Rivolta R, Parenti M, Palazzi P, Zanussi C. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplantation Proceedings 1991;23(1 Pt 2):969-71
66. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98(8): 734-41
67. Schulze von R, Langkopf B, Sziegoleit W. The effect of dipyridamole on the results of allogenic kidney transplantation [Der Einfluss von Dipyridamol auf die Ergebnisse der allogenen Nieren-transplantation]. Zeitschrift für Urologie und Nephrologie 1990;83(5):255-9
68. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double blind study. Kidney International 1994;45(5):1477-83
69. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Antiplatelet therapy in expanded polytetrafluoroethylene (EPTFE) graft thrombosis: results of a randomized double blind study [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):388
70. Mileti M, De PG, Bacchi M, Ogliari V, Pecchini F, Bufano G, et al. A trial to evaluate the efficacy of picotamide in preventing thrombotic occlusion of the vascular access in hemodialysis patients. Journal of Nephrology 1995;8(2): 167-72
71. Taber T, Maikranz P, Haag B, Dilley R, Gaylord G. Hemodialysis vascular graft stenosis may be altered by lowmolecular weight dextran (LMD), but not by aspirin (ASA) [abstract]. Journal of the American Society of Nephrology 1992;3(3):397
72. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal 2005;149(5):869-75
73. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal ofMedicine 2001;344(25):1888-94
74. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 2007;357(20):2001-15
75. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005;45(3):473-84
76. Baigent C, UK-HARP Steering Committee. Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):437A
77. Zäuner I, Böhler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Nephrology Dialysis Transplantation 1994;9(6):619-22
78. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348(9038):1329-39
79. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Safety 1999;21(4):325-35
80. Caravaca F, Lopez-Minguez JR, Arrobas M, Cubero J, Pizarro JL, Cid MC, et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrology Dialysis Transplantation 1995;10(9):1720-4
81. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). American Journal of Cardiology 2005;95(5):581-5
82. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, Ksiazek A, Orlowska G, Janicki K. The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. International Urology & Nephrology 1990;22(6):561-6
83. Mercado N, Brugts JJ, Ix JH, ShlipakMG, Dixon SR, Gersh BJ, et al. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). American Journal of Cardiology 2008;102(9):1151-5
84. Gorter JW. Preventive treatment of patients after non-disabling cerebral ischaemia of presumed arterial origin: Comparative randomized study with intensive anticoagulant therapy or aspirin treatment [Preventieve behandeling van patienten na niet-invaliderende cerebrale ischemie door vermoedelijk arteriele oorzaak: Vergelijkend, gerandomiseerd onderzoek met intensieve antistollingstherapie of behandeling met acetylsalicylzuur]. Nederlands Tijdschrift voor Geneeskunde 1998;142(6):306-12
85. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2002;136(2):161-72
86. Huang J. Investigation of platelet function and aspirin resistance in chronic dialysis patient. Available at http://www.clinicaltrials.gov/ct2/show/NCT01045785 (accessed 24 December 2012)
87. Janicki K, Bojarska-Szmygin A, Pietura R, Janicka L. Preventive effects of ticlopidine on the incidence of late AV fistula thrombosis complications in haemodialyses patients. Annales Universitatis Mariae Curie-Sklodowska-Sectio d-Medicina 2003;58(1):215-8
88. Kamper AM, Lins RL, Zachee P, Van Bergen S, Hosten S, Daelemans R. Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron 1997;77(4):484-5
89. Kim KM, Kim HW, Lee JH, Chang JW, Park JS, Kim SB. Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. Peritoneal Dialysis International 2009;29(2):178-81
90. Lang J, Cao H, Wei A. Comparative study on effect of Panax notoginseng and ticlid in treating early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine] 1998;18(12):727-9
91. Lee GS, Choong HL, Chiang GSC, Woo KT. Three-year randomized controlled trial of dipyridamole and lowdose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997;3(1):117-21
92. Lindsay RM, Ferguson D, Prentice CR, Burton JA, McNicol GP. Reduction of thrombus formation on dialyser membranes by aspirin and RA 233. Lancet 1972;2(7790): 1287-90
93. Minakata T, Yonemoto S, Nomura K, Yoshida H. Antiplatelet drugs in diabetic hemodialysis patients: comparison of aspirin vs ticlopidine hydrochloride [abstract]. 35th Congress, European Renal Association, European Dialysis and Transplantation Association; Rimini (Italy). 1998:240
94. Movchan EA, Chuprova AV, Tov NL, Vol'vich NV. Desaggregation therapy of acute glomerulonephritis. Klinicheskaia Meditsina 2001;79(12):44-7
95. Scarpioni R, Michieletti E, Cristinelli L, Ugolotti U, Scolari F, Venturelli C, et al. Atherosclerotic renovascular disease: medical therapy versus medical therapy plus renal artery stenting in preventing renal failure progression: the rationale and study design of a prospective, multicenter and randomized trial (NITER). Journal of Nephrology 2005;18 (4):423-8
96. Perkovic V, Nicholls KM, Foreman A, Becker GJ. A randomised controlled trial of cardiovascular risk factor modification in end stage renal failure [abstract]. Nephrology 2004;9(Suppl 1):A16
97. Perkovic V, Nicholls KM, Foreman A, Walker RG, Becker GJ. A randomised controlled trial of cardiovascular risk factor modification in end stage kidney disease [abstract]. Journal of the American Society of Nephrology 2004;15: 377A-8A
98. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. British Medical Journal Clinical Research Ed. 1988;296(6618):313-6
99. Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. New England Journal of Medicine 1989; 321(3):129-35
100. Physician Health Study. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351(9098):233-41
101. Marcantoni C, Zanoli L, Rastelli S, Tripepi G, Matalone M, Di Landro D, et al. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. Journal of Nephrology 2009;22(1):13-6
102. Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008; 117(21):2752-60
103. Kanjwal K, Haller S, Steffes M, Virmani R, Shapiro JI, Burket MW, et al. Complete versus partial distal embolic protection during renal artery stenting. Catheterization & Cardiovascular Interventions 2009;73(6):725-30
104. Rubin J, Adair C, Barnes T, Bower JD. Augmentation of peritoneal clearance by dipyridamole. Kidney International 1982;22(6):658-61
105. Salter MC, Crow MJ, Donaldson DR, Roberts TG, Rajah SM, Davison AM. Prevention of platelet deposition and thrombus formation on hemodialysis membranes: a double-blind randomized trial of aspirin and dipyridamole. Artificial Organs 1984;8(1):57-61
106. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008;358(6): 580-91
107. Halstenson CE, Swan SK, Collins AJ, Ellefson J, Parr K, Blue J, et al. Pharmacologic profile of diaspirin crosslinked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 1994;5(3):451
108. Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ. Pharmacologic profile of diaspirin crosslinked hemoglobin in hemodialysis patients. American Journal of KidneyDiseases 1995;26(6):918-23
109. Swan SK, Halstenson CE, Collins AJ, Ellefson J, Parr K, Blue J, et al. Pharmacodynamic and pharmacokinetic parameters of diaspirin cross-linked hemoglobin (DCLHB) in hemodialysis (HD) patients [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:559
110. Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM, Ohman EM, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrology Dialysis Transplantation 2005;20 (10):2105-12
111. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000;355(9201):337-45
112. Trimarchi H, Young P, Forrester M, Schropp J, Pereyra H, Freixas E. Clopidogrel diminishes hemodialysis access graft thrombosis. Nephron 2006;102(3-4):c128-32
113. Van Der Zaag ES, Legemate DA, Tangelder MJ, Algra A, Lawson JA, Eikelboom BC. Prevention of occlusions after bypass surgery with anticoagulant agents or acetylsalicylic acid: a randomised comparison. Nederlands Tijdschrift voor Geneeskunde 2001;145(36):1765
114. Vienken JA. Thromboxane generation by dialysis membranes is controlled by aspirin administration [abstract]. Nephrology Dialysis Transplantation 1996;11: 1472
115. Yoshikawa N, Ito H. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy-is it relevant for adult patients?. Nephrology Dialysis Transplantation 1999;14(5):1097-9
116. Zibari GB, Gadallah MF, Landreneau MD, McMillian R, Bridges R, Costley K, et al. The efficacy and complications of aspirin versus heparin in postoperative prophylaxis against thrombosis in newly placed hemodialysis access [abstract]. Journal of the American Society of Nephrology 1995;6(3):507. References to ongoing studies
117. Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, et al. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrology 2009;10:1
118. Irish A, FAVOURED Study Group. High rate of screening failure in the FAVOURED study [abstract]. Nephrology 2009;14(Suppl 1):A45
119. Taipei Veterans General Hospital, Taiwan. Efficacy of monitoring of aspirin responsiveness in the prevention of cardiovascular events and decrease in bleeding complications in patients with end-stage kidney disease undergoing hemodialysis. Available at http://clinicaltrials.gov/ct2/show/NCT01198379 (accessed 12 November 2012)
120. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrology Dialysis Transplantation 1999;14(3):648-54
121. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E. Special characteristics of atherosclerosis in chronic renal failure. Clinical Nephrology 2003;60 Suppl 1:S13-21
122. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine 2004;351(13): 1285-95
123. Australia, New Zealand Dialysis, Transplant Registry. The 32nd Annual Report 2009 Report-Data to 2008. http://www.anzdata.org.au/v1/report?2009.html (accessed 12 November 2012)
124. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86
125. Antithrombotic Trialists' (ATT) Collaboration. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678): 1849-60
126. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW,Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. Journal of the American Society of Nephrology 2006;14(7 Suppl 2):S131-8
127. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal of the American College of Cardiology 2003;42(2):201-8
128. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of shortand long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008; 155(4):687-93
129. Bonomini V, Vangelista A, Stefoni S, ScolariMP, FrascaGM, Raimondi C. Use of defibrotide in renal transplantation in man. Haemostasis 1986;16 Suppl 1:48-50
130. Caring for Australasians with Renal Impairment (CARI). Vascular access. http://www.cari.org.au/dialysis valist published.php (accessed 12 November 2012)
131. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33
132. Coleman CI, Tuttle LA, Teevan C, Baker WL, White CM, Reinhart KM. Antiplatelet agents for the prevention of arteriovenous fistula and graft thrombosis: a meta analysis. International Journal of Clinical Practice 2010;64 (9):1239-44
133. Collins AJ. Cardiovascular mortality in end-stage renal disease. American Journal of the Medical Sciences 2003;325 (4):163-7
134. Curtis BM, Parfrey PS. Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management. Cardiology Clinics 2005;23(3):275-84
135. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782-9
136. Dikow R, ZeierM, Ritz E. Pathophysiology of cardiovascular disease and renal failure. Cardiology Clinics 2005;23(3): 311-7
137. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44(4): 398-404
138. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International 1995;47(1):186-92
139. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney International-Supplement 2005;99:S25-9
140. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004;351(13):1296-305
141. GRADE Working Group. Grading of Recommendations Assessment, Development and Evaluation (GRADE). http://www.gradeworkinggroup.org/index.htm
142. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327 (7414):557-60
143. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
144. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(1): 105-10
145. Kasiske BL. Cardiovascular disease after renal transplantation. Seminars in Nephrology 2000;20(2): 176-87
146. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Seminars in Dialysis 2006;19(4):317-22
147. National Kidney Foundation. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. http://www.kidney.org/professionals/kdoqi/guidelines?cvd/guide3.htm (accessed 12 November 2012)
148. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine 2004;164 (6):659-63
149. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006;67(2):224-8
150. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of Internal Medicine 2001;134(8):629-36
151. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. American Heart Journal 2002;144(2):226-32
152. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesityrelated health risk factors, 2001. JAMA 2003;289(1):76-9
153. Mosenkis A, Berns JS. Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease. Seminars in Dialysis 2004;17(5):411-5
154. National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm (accessed 12 November 2012)
155. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases 2006;48 (5):739-51
156. Ojo AO, Hanson JA,Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney International 2000;57(1): 307-13
157. Osborn G, Escofet X, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database of Systematic Reviews 2008, Issue 4
158. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Annals of Internal Medicine 2007; 147(12):840-53
159. Remppis A, Ritz E. Cardiac problems in the dialysis patient: beyond coronary disease. Seminars in Dialysis 2008;21(4): 319-25
160. Remuzzi G. Bleeding in renal failure. Lancet 1988;1(8596): 1205-8
161. Renal Association. Cardiovascular disease in CKD. http://www.renal.org/Clinical/GuidelinesSection/CardiovascularDiseaseInCKD.aspx#Rationale3 (accessed 12 November 2012)
162. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. Journal of the American Society of Nephrology 2001;12(2):218-25
163. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42(5):1050-65
164. Scheen AJ. Medications in the kidney. Acta Clinica Belgica 2008;63(2):76-80
165. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published metaanalyses. BMJ 2003;326(7387):472
166. Sterne JA, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011. Available from www.cochranehandbook. org
167. Taji Y, Kuwahara T, Shikata S, Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clinical & Experimental Nephrology 2006;10(4):268-73
168. US Renal Data System. USRDS 2010 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. http://www.usrds.org/atlas10.aspx (accessed 12 November 2012)
169. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. Journal of the American Society of Nephrology 2008;19(1):135-40
170. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. Journal of the American Society of Nephrology 2004;15(5):1307-15
171. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases 2004;44(2):198-206
172. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. American Journal of Kidney Diseases 2006;48(3):392-401
173. Zwaginga JJ, IJsseldijkMJ, de Groot PG, Vos J, de Bos Kuil RL, Sixma JJ. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. Arteriosclerosis & Thrombosis 1991;11(3): 733-44
174. Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. American Journal of Kidney Diseases 2013;61 (1):112-22
175. Razavian M, Di Micco L, Palmer SC, Craig JC, Perkovic V, Zoungas S, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2010, Issue 11